These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 195708)

  • 21. Immunology of herpesvirus infection: immunity to herpes simplex virus in eye infections.
    Meyers RL; Chitjian PA
    Surv Ophthalmol; 1976; 21(2):194-204. PubMed ID: 185741
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. II. Bifunctional clones with cytotoxic and virus-induced proliferative activities exhibit herpes simplex virus type 1 and 2 specific or type common reactivities.
    Yasukawa M; Zarling JM
    J Immunol; 1984 Nov; 133(5):2736-42. PubMed ID: 6207243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Appearanc of cytotoxic cells within the bronchus after local infection with herpes simplex virus.
    Clancy R; Rawls WE; Jagannath S
    J Immunol; 1977 Sep; 119(3):1102-5. PubMed ID: 197165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of recognition of herpes simplex virus type 1-infected cells by natural killer cells.
    López-Guerrero JA; Alarcón B; Fresno M
    J Gen Virol; 1988 Nov; 69 ( Pt 11)():2859-68. PubMed ID: 2846762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effector cell involved in cell-mediated cytotoxicity to cells infected with herpes simplex virus type 1.
    Heron I; Moller-Larsen A; Berg K
    Infect Immun; 1977 Apr; 16(1):48-53. PubMed ID: 194839
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro.
    Cunningham AL; Noble JR
    J Clin Invest; 1989 Feb; 83(2):490-6. PubMed ID: 2464000
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental immunosuppression induced by herpes simplex virus.
    Cappel R; Henry C; Thiry L
    Arch Virol; 1975; 49(1):67-72. PubMed ID: 172950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A possible role for polymorphonuclear leucocytes in the defence against recrudescent herpes simplex virus infection in man.
    Russell AS; Miller C
    Immunology; 1978 Mar; 34(3):371-8. PubMed ID: 640713
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulation of peripheral blood lymphocytes by herpes simplex virus in vitro.
    Scriba M
    Infect Immun; 1974 Sep; 10(3):430-6. PubMed ID: 4372170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells.
    Oleske JM; Ashman RB; Kohl S; Shore SL; Starr SE; Wood P; Nahmias AJ
    Clin Exp Immunol; 1977 Mar; 27(3):446-53. PubMed ID: 193661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-dependent cell-mediated cytotoxicity to target cells infected with herpes simplex viruses.
    Shore SL; Melewicz FM; Milgrom H; Nahmias AJ
    Adv Exp Med Biol; 1976; 73 Pt B():217-27. PubMed ID: 187023
    [No Abstract]   [Full Text] [Related]  

  • 32. In vitro induction of human cell-mediated cytotoxicity directed against herpes simplex virus-infected cells: characterization of the effector lymphocyte.
    Rola-Pleszczynski M
    J Immunol; 1980 Oct; 125(4):1475-80. PubMed ID: 6967905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity.
    Paya CV; McKean DJ; Segal DM; Schoon RA; Showalter SD; Leibson PJ
    J Immunol; 1989 Jan; 142(2):666-71. PubMed ID: 2536060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced lysis of herpes simplex virus type 1-infected mouse cell lines by NC and NK effectors.
    Colmenares C; Lopez C
    J Immunol; 1986 May; 136(9):3473-80. PubMed ID: 2420891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell-mediated immunity to herpes simplex virus in man.
    Russell AS
    Am J Clin Pathol; 1973 Dec; 60(6):826-30. PubMed ID: 4357123
    [No Abstract]   [Full Text] [Related]  

  • 36. T-cell-mediated cytotoxicity against herpes simplex virus-infected target cells.
    Pfizenmaier K; Starzinski-Powitz A; Röllinghoff M; Falks D; Wagner H
    Nature; 1977 Feb; 265(5595):630-2. PubMed ID: 193023
    [No Abstract]   [Full Text] [Related]  

  • 37. The possible local synthesis of antibodies to herpes simplex virus in normal cerebrospinal fluid.
    Russell AS
    Can J Neurol Sci; 1976 Nov; 3(4):219-21. PubMed ID: 187307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune response to herpes simplex virus in patients with recurrent herpes labialis. II. Relationship between interferon production and cytotoxic responses.
    Tsutsumi H; Bernstein JM; Riepenhoff-Talty M; Ogra PL
    Pediatr Res; 1986 Sep; 20(9):905-8. PubMed ID: 3018660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heteroconjugate antibodies enhance cell-mediated anti-herpes simplex virus immunity in vivo.
    Voss LM; David CS; Showalter SD; Paya CV; Leibson PJ
    Int Immunol; 1992 Mar; 4(3):417-20. PubMed ID: 1314641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune response in humans after vaccination with vaccinia virus: generation of a virus-specific cytotoxic activity by human peripheral lymphocytes.
    Perrin LH; Zinkernagel RM; Oldstone MB
    J Exp Med; 1977 Oct; 146(4):949-69. PubMed ID: 302316
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.